Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service vitreoretinal surgery cases in New Mexico: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 8 | 528 | 40% |
| 2020 | 7 | 483 | 43% |
| 2021 | 9 | 573 | 46% |
| 2022 | 8 | 511 | 50% |
| 2023 | 8 | 562 | 53% |
| 2024 | 8 | 477 | 54% |
| 2025 from claims | – | 427 345–502 | 54% |
| 2026 forecast | – | 426 334–535 | 55% |
| 2027 forecast | – | 429 318–567 | 55% |
| 2028 forecast | – | 431 305–595 | 56% |
| 2029 forecast | – | 434 295–622 | 56% |
| 2030 forecast | – | 437 286–648 | 56% |
Pars plana vitrectomy and retinal detachment repair. Professional codes (what the surgeon bills): CPT 67036, 67040, 67041, 67042, 67108, 67113.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Mexico; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 46% hospital outpatient, 54% surgery center. The share outside the hospital has moved +6 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 94 | 7,488−1.9%/yr | −1.9%/yr | 2.3 | 59% | 8,080 in 2030+1.3%/yr |
| Arizona | 32 | 2,892−3.5%/yr | −3.5%/yr | 3.9 | 99% | 3,110 in 2030+1.2%/yr |
| Washington | 30 | 1,954−4.2%/yr | −4.2%/yr | 2.6 | 60% | 1,820 in 2030−1.2%/yr |
| Colorado | 31 | 1,941+1%/yr | +1%/yr | 4.0 | 75% | 2,470 in 2030+4.1%/yr |
| Oregon | 16 | 1,238−2.8%/yr | −2.8%/yr | 3.0 | 41% | 1,270 in 2030+0.4%/yr |
| Utah | 15 | 1,023−2.3%/yr | −2.3%/yr | 4.7 | 59% | 990 in 2030−0.6%/yr |
| Nevada | 10 | 723−1.9%/yr | −1.9%/yr | 2.5 | 8% | 850 in 2030+2.7%/yr |
| Idaho | 6 | 497+2.3%/yr | +2.3%/yr | 2.5 | 77% | 620 in 2030+3.7%/yr |
| Montana | 5 | 349−0.8%/yr | −0.8%/yr | 1.8 | 51% | 340 in 2030−0.3%/yr |
| Hawaii | 5 | 294−3.5%/yr | −3.5%/yr | 2.3 | 95% | 300 in 2030+0.3%/yr |
| Alaska | 1 | 154−1%/yr | −1%/yr | 1.3 | 100% | 130 in 2030−3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Cataract & MIGS | 34 | 9,620−3.6%/yr | −3.6%/yr | 41.10.9× | 92% | 10,700 in 2030+1.8%/yr |
Vitreoretinal surgery in every state, and its device makers · Every procedure market in New Mexico · Every state · Compare with California
Alcon leads with 68% of company spending on these surgeons in 2025, −7 pts on 2024.
In 2025, 7 companies reported engagement with New Mexico’s surgeons worth $12K in consulting, speaking, meals and travel tied to these products, about $1,561 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 0 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.